1)Antimicrobial Resistance:Tackling a Crisis for the Future Health and Wealth of Nations. https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf
2)Giske CG, et al:ReAct-Action on Antibiotic Resistance. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 52:813-821, 2008
3)津谷喜一郎,他:ATC/DDDとは何か 医薬品の合理的使用を目指すものさし.薬剤疫9:53-58, 2005
4)WHO Collaborating Centre for Drug Statistics Methodology:ATC/DDD Index 2017. http://www.whocc.no/atc_ddd_index/
5)Ibrahim OM, et al:Antimicrobial use metrics and benchmarking to improve stewardship outcomes:methodology, opportunities, and challenges. Infect Dis Clin North Am 28:195-214, 2014
isolates at 203 Japanese hospitals in 2010. Infection 41:415-423, 2013
7)Muraki Y, et al:Japanese antimicrobial consumption surveillance:first report on oral and parenteral antimicrobial consumption in Japan(2009-2013). J Glob Antimicrob Resist 7:19-23, 2016
8)Dellit TH, et al:Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 44:159-177, 2007
9)首相官邸,国際的に脅威となる感染症対策関係閣僚会議:薬剤耐性(AMR)対策アクションプラン(本体).http://www.kantei.go.jp/jp/singi/kokusai_kansen/pdf/yakuzai_honbun.pdf
10)Barlam TF, et al:Implementing an Antibiotic Stewardship Program:Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis 62:e51-77, 2016
11)Muñoz P, et al:Antifungal stewardship in daily practice and health economic implications. Mycoses 58 Suppl 2:14-25, 2015